DNA-sequencing identified CNV-high and MSI-high biomarkers with significantly unfavorable and favorable, respectively, prognostic effects in PT-DLBCL, rather than MYD88/CD79B mutations and the MCD genetic subtype (2, 16, 29). The gene discussed is MYD88; the disease is diffuse large B-cell lymphoma.